289 related articles for article (PubMed ID: 29433987)
21. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.
McKiernan J; Donovan MJ; Margolis E; Partin A; Carter B; Brown G; Torkler P; Noerholm M; Skog J; Shore N; Andriole G; Thompson I; Carroll P
Eur Urol; 2018 Dec; 74(6):731-738. PubMed ID: 30237023
[TBL] [Abstract][Full Text] [Related]
22. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening.
Assel M; Dahlin A; Ulmert D; Bergh A; Stattin P; Lilja H; Vickers AJ
Eur Urol; 2018 Jun; 73(6):961-967. PubMed ID: 29066048
[TBL] [Abstract][Full Text] [Related]
23. Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7-10 Prostate Cancer in Biopsy-naïve Men.
Boesen L; Nørgaard N; Løgager V; Balslev I; Bisbjerg R; Thestrup KC; Jakobsen H; Thomsen HS
Eur Urol Oncol; 2019 May; 2(3):311-319. PubMed ID: 31200846
[TBL] [Abstract][Full Text] [Related]
24. Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.
Vickers AJ; Wolters T; Savage CJ; Cronin AM; O'Brien MF; Pettersson K; Roobol MJ; Aus G; Scardino PT; Hugosson J; Schröder FH; Lilja H
Eur Urol; 2009 Nov; 56(5):753-60. PubMed ID: 19682790
[TBL] [Abstract][Full Text] [Related]
25. The Cost-Effectiveness of Prostate Cancer Detection with the Use of Prostate Health Index.
Heijnsdijk EA; Denham D; de Koning HJ
Value Health; 2016; 19(2):153-7. PubMed ID: 27021748
[TBL] [Abstract][Full Text] [Related]
26. A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening.
Vickers AJ; Gupta A; Savage CJ; Pettersson K; Dahlin A; Bjartell A; Manjer J; Scardino PT; Ulmert D; Lilja H
Cancer Epidemiol Biomarkers Prev; 2011 Feb; 20(2):255-61. PubMed ID: 21148123
[TBL] [Abstract][Full Text] [Related]
27. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up.
Rider JR; Wilson KM; Sinnott JA; Kelly RS; Mucci LA; Giovannucci EL
Eur Urol; 2016 Dec; 70(6):974-982. PubMed ID: 27033442
[TBL] [Abstract][Full Text] [Related]
28. A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam.
Roobol MJ; Zhu X; Schröder FH; van Leenders GJ; van Schaik RH; Bangma CH; Steyerberg EW
Eur Urol; 2013 Apr; 63(4):627-33. PubMed ID: 22841675
[TBL] [Abstract][Full Text] [Related]
29. Results of Prostate Cancer Screening in a Unique Cohort at 19yr of Follow-up.
Osses DF; Remmers S; Schröder FH; van der Kwast T; Roobol MJ
Eur Urol; 2019 Mar; 75(3):374-377. PubMed ID: 30420254
[TBL] [Abstract][Full Text] [Related]
30. Prostate cancer risk assessment in men with an initial P.S.A. below 3 ng/mL: results from the Göteborg randomized population-based prostate cancer screening trial.
Frånlund M; Arnsrud Godtman R; Carlsson SV; Lilja H; Månsson M; Stranne J; Hugosson J
Scand J Urol; 2018 Aug; 52(4):256-262. PubMed ID: 30241447
[TBL] [Abstract][Full Text] [Related]
31. Screening for prostate cancer.
Ilic D; Neuberger MM; Djulbegovic M; Dahm P
Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794
[TBL] [Abstract][Full Text] [Related]
32. Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results.
Beckmann K; Crawley D; Nordström T; Aly M; Olsson H; Lantz A; Binti Abd Jalal N; Garmo H; Adolfsson J; Eklund M; Van Hemelrijck M
JAMA Netw Open; 2019 Nov; 2(11):e1914689. PubMed ID: 31693126
[TBL] [Abstract][Full Text] [Related]
33. A population-based study on the association between educational length, prostate-specific antigen testing and use of prostate biopsies.
Nordström T; Bratt O; Örtegren J; Aly M; Adolfsson J; Grönberg H
Scand J Urol; 2016; 50(2):104-9. PubMed ID: 26625178
[TBL] [Abstract][Full Text] [Related]
34. Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study.
Rider JR; Sandin F; Andrén O; Wiklund P; Hugosson J; Stattin P
Eur Urol; 2013 Jan; 63(1):88-96. PubMed ID: 22902040
[TBL] [Abstract][Full Text] [Related]
35. Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer.
Buzzoni C; Auvinen A; Roobol MJ; Carlsson S; Moss SM; Puliti D; de Koning HJ; Bangma CH; Denis LJ; Kwiatkowski M; Lujan M; Nelen V; Paez A; Randazzo M; Rebillard X; Tammela TL; Villers A; Hugosson J; Schröder FH; Zappa M
Eur Urol; 2015 Nov; 68(5):885-90. PubMed ID: 25791513
[TBL] [Abstract][Full Text] [Related]
36. Long-term Outcomes for Men in a Prostate Screening Trial with an Initial Benign Prostate Biopsy: A Population-based Cohort.
Palmstedt E; Månsson M; Frånlund M; Stranne J; Pihl CG; Hugosson J; Arnsrud Godtman R
Eur Urol Oncol; 2019 Nov; 2(6):716-722. PubMed ID: 31411967
[TBL] [Abstract][Full Text] [Related]
37. Prostate-specific antigen (PSA) screening and follow-up investigations in Māori and non-Māori men in New Zealand.
Obertová Z; Scott N; Brown C; Hodgson F; Stewart A; Holmes M; Lawrenson R
BMC Fam Pract; 2014 Aug; 15():145. PubMed ID: 25154420
[TBL] [Abstract][Full Text] [Related]
38. The Stockholm-3 (STHLM3) Model can Improve Prostate Cancer Diagnostics in Men Aged 50-69 yr Compared with Current Prostate Cancer Testing.
Eklund M; Nordström T; Aly M; Adolfsson J; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Presti JC; StLezin M; Clements M; Egevad L; Grönberg H
Eur Urol Focus; 2018 Sep; 4(5):707-710. PubMed ID: 28753803
[TBL] [Abstract][Full Text] [Related]
39. A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort.
Braun K; Sjoberg DD; Vickers AJ; Lilja H; Bjartell AS
Eur Urol; 2016 Mar; 69(3):505-11. PubMed ID: 25979570
[TBL] [Abstract][Full Text] [Related]
40. Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study.
Young GJ; Harrison S; Turner EL; Walsh EI; Oliver SE; Ben-Shlomo Y; Evans S; Lane JA; Neal DE; Hamdy FC; Donovan JL; Martin RM; Metcalfe C
BMJ Open; 2017 Oct; 7(10):e017729. PubMed ID: 29084797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
